Sana Biotechnology, Inc. — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Sana Biotechnology disclosed clinical and preclinical progress on two programs: (1) SC451, a hypoimmune stem cell-derived islet cell therapy for type 1 diabetes, targeting IND filing and Phase 1/2 initiation in 2026 with no immunosuppression required; and (2) in vivo CAR-T programs (SG293 in non-Hodgkin lymphoma, SG227 in multiple myeloma) using fusosome technology, with SG293 showing potent CD8+ T cell transduction and B cell depletion in nonhuman primate studies and potential first-in-human data sharing in 1H 2027. The presentation details successful clinical proof-of-concept from UP421 (hypoimmune islet transplant in one T1D patient showing 52-week graft survival without immunosuppression) and nonclinical validation of the fusosome platform.
Why this rating
Meaningful clinical validation (52-week human data) + two late-stage programs approaching IND/trials represent real near-term catalysts. For ~$295M market-cap biotech, IND filings and Phase 1 initiation are material milestones. However, early-stage, unproven therapies carry execution risk; significance tempered by early-stage nature and reliance on single patient proof-of-concept.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $3.85 ▼ 0.10% | at our read · unknown $3.85 | +10 min · unknown $3.85 ▲ 0.00% | +30 min · unknown $3.85 ▲ 0.00% | +1 hr · unknown $3.85 ▲ 0.00% | +4 hrs pending |
The stock had already moved +0.10% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.